Introduction
In addition to the above annotation challenges, technical limitations of NGS can also lead to 7 0 inaccurate variant calls. Several genes contain coding sequences that can pose several technical and temporal expression from published literature (Figure 1) . Exon-specific expression data 1 0 1 were extracted from the Genotype-Tissue Expression Project (GTEx) on 01/15/18. GTEx was were queried from the Genome Aggregation Database (gnomAD) 1 3 , and exons containing such LoFs were flagged. An allele frequency of 0.3% was chosen since variants in hearing loss genes 1 0 7 that are above this frequency can be considered likely benign as defined by Duzkale et al All coding and noncoding exons in the primary transcript were numbered sequentially. Coding
and noncoding exons in minor transcripts were also numbered separately and sequentially per transcript. Transcripts were aligned and viewed using Alamut (Version 2.6.1 Interactive
Biosoftware). Each minor transcript was given a different letter that was added after the exon 1 1 3 number. For example, if there were two transcripts with unique alternate exon 1, they were 1 1 4 numbered as 1A and 1B. To define a minimal curated transcript list, unique exons were listed in 1 1 5 the minimal number of minor transcripts and the designated longest transcript contained the most 1 1 6
coding bases (Table 1, Supplemental Tables 1-3) . 1 1 7
Exons were classified as "clinically significant", "uncertain significance", or "clinically Figure 1C ). Exons were classified as "clinically significant" if there was no evidence they were alternatively spliced, they did not contain high frequency exonic LoF 1 2 0 variants, or they were supported by tissue-specific inner ear expression in the literature.
likely to be benign. The ATP6V1B1 exon 1 contained a start loss variant (c.2T>C; p.M1?) that
was present in 40% total alleles in gnomAD, including 23,280 homozygotes. It is possible that
the exon start is erroneously annotated or that re-initiation might occur elsewhere, including at 1 7 1 any of the two downstream methionines in this exon. However, there is currently no functional data to support either possibility or to rule out potential re-initiation at downstream exons. We be carefully interpreted. unique exons (Figure 2A and Supplementary An illustrative example in this category is the EDN3 gene known to cause Waardenburg . This gene has 5 RefSeq transcripts sharing coding exons 1-3 and 5 supports usage of the exon 4 (and not 4d) splice donor site, suggesting that exon 4d is not
biologically relevant (Figure 4B ). Similarly, exon 8c in the NM_181460.3 transcript of the PAX3 gene is unlikely to be biologically 2 2 0 relevant as supported by lack of its expression (GTEx database) and the presence of a putative . This gene has 13 curated RefSeq transcripts. deep intronic consequence were interpreted. . This gene has 2 curated RefSeq variants across those exons ( Figure 2C) . These variants interpreted as clinically significant will 2 5 2 all require further assessment to ensure sufficient evidence is present to implicate them in 2 5 3 hearing loss. This highlights the importance of our transcript curation approach and the impact it Due to its genetic heterogeneity, most clinical genetics laboratories use targeted or exome-based 2 5 7 panels to sequence a comprehensive set of genes known to cause hearing loss. Although very We sought to identify regions in a set of 109 hearing loss genes that are technically challenging 2 6 2 to sequence using current short read (100-150bp) NGS in clinical laboratories. We used clinical . We identified 43 well- ( Supplementary Table 4 and methods). Of those, 31 exons were sequenced to an overall 2 7 0 coverage of ~600x using a different targeted capture (average % baited exons: 95%) and longer 2 7 1 reads (150bp), but still had low quality metrics ( Supplementary Table 4 ).
7 2
The 43 regions included exons with high homology to other genomic sequences (n=21 exons in and TPRN) (Figure 5) . It is unlikely that sequence variants in all 43 exons will be reliably variant calls in those exons should be highly expected. Finally, we use exon-level NGS quality metrics to highlight regions that are inaccessible to recovered with longer reads and improved bioinformatics pipelines. Until then, however, it is 3 0 5
highly important that different ancillary assays, such as Sanger sequencing, be validated to 3 0 6 accurately capture sequence variants in those regions. In summary, we recommend that our transcript selection framework and exon classification 3 0 8 system be used in other disease areas for more efficient and accurate variant interpretation, and 3 0 9
to avoid erroneous annotations and, potentially, misdiagnoses. Cummins C, Clapham P, Gil L, Giron CG, Gordon L, Hourlier T, Hunt SE, Janacek SH, Petit C: Usherin, the defective protein in Usher syndrome type IIA, is likely to be a component of interpreted variation, LP/P variants were pulled from our internal database (also in ClinVar) and The high frequency loss of function variant is pulled from gnomAD and is located in the exon sequences; and GC-rich first exon in the potassium channel, KCNQ1 (middle). MQ and coverage
